These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 34624446)

  • 1. Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa.
    Yu S; Pu X; Ahmed MU; Yu HH; Mutukuri TT; Li J; Zhou QT
    Int J Pharm; 2021 Dec; 610():121160. PubMed ID: 34624446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalable Nanocomposite Microparticles with Enhanced Dissolution and Superior Aerosol Performance.
    Zhu C; Chen J; Yu S; Que C; Taylor LS; Tan W; Wu C; Zhou QT
    Mol Pharm; 2020 Sep; 17(9):3270-3280. PubMed ID: 32643939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
    Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
    Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections.
    Yu S; Wang S; Zou P; Chai G; Lin YW; Velkov T; Li J; Pan W; Zhou QT
    Int J Pharm; 2020 Feb; 575():118915. PubMed ID: 31816354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
    Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spray dried inhalable ivacaftor co-amorphous microparticle formulations with leucine achieved enhanced in vitro dissolution and superior aerosol performance.
    Guan J; Yuan H; Yu S; Mao S; Tony Zhou Q
    Int J Pharm; 2022 Jun; 622():121859. PubMed ID: 35643348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of inhalable liposomal powder formulations and evaluation of their in vitro drug delivery behavior in Calu-3 human lung epithelial cells.
    Yu S; Yuan H; Chai G; Peng K; Zou P; Li X; Li J; Zhou F; Chan HK; Zhou QT
    Int J Pharm; 2020 Aug; 586():119570. PubMed ID: 32593649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
    Millar BC; Rendall JC; Downey DG; Moore JE
    J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.
    Chen J; Ahmed MU; Zhu C; Yu S; Pan W; Velkov T; Li J; Tony Zhou Q
    Int J Pharm; 2021 Mar; 596():120211. PubMed ID: 33486036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
    Alhajj N; Yahya MFZR; O'Reilly NJ; Cathcart H
    Eur J Pharm Sci; 2024 Jan; 192():106654. PubMed ID: 38013123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide.
    d'Angelo I; Casciaro B; Miro A; Quaglia F; Mangoni ML; Ungaro F
    Colloids Surf B Biointerfaces; 2015 Nov; 135():717-725. PubMed ID: 26340361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.
    Wang W; Zhou QT; Sun SP; Denman JA; Gengenbach TR; Barraud N; Rice SA; Li J; Yang M; Chan HK
    AAPS J; 2016 Mar; 18(2):372-84. PubMed ID: 26603890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
    Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
    J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation.
    Mangal S; Park H; Zeng L; Yu HH; Lin YW; Velkov T; Denman JA; Zemlyanov D; Li J; Zhou QT
    Int J Pharm; 2018 Sep; 548(1):443-453. PubMed ID: 30008433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.
    Durfey SL; Pipavath S; Li A; Vo AT; Ratjen A; Carter S; Morgan SJ; Radey MC; Grogan B; Salipante SJ; Welsh MJ; Stoltz DA; Goss CH; McKone EF; Singh PK
    mBio; 2021 Dec; 12(6):e0314821. PubMed ID: 34903059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
    Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
    Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward Repositioning Niclosamide for Antivirulence Therapy of Pseudomonas aeruginosa Lung Infections: Development of Inhalable Formulations through Nanosuspension Technology.
    Costabile G; d'Angelo I; Rampioni G; Bondì R; Pompili B; Ascenzioni F; Mitidieri E; d'Emmanuele di Villa Bianca R; Sorrentino R; Miro A; Quaglia F; Imperi F; Leoni L; Ungaro F
    Mol Pharm; 2015 Aug; 12(8):2604-17. PubMed ID: 25974285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.
    Mangal S; Huang J; Shetty N; Park H; Lin YW; Yu HH; Zemlyanov D; Velkov T; Li J; Zhou QT
    Int J Pharm; 2019 Apr; 561():102-113. PubMed ID: 30797863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the Impacts of Surface Compositions on the In-Vitro Dissolution and Aerosolization of Co-Spray-Dried Composite Powder Formulations for Inhalation.
    Mangal S; Xu R; Park H; Zemlyanov D; Shetty N; Lin YW; Morton D; Chan HK; Li J; Zhou QT
    Pharm Res; 2018 Nov; 36(1):6. PubMed ID: 30406281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
    Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.